Synaptogenix | Neurotrope to Present Additional Phase 2 Data at the 11th Edition of Clinical Trials on Alzheimer’s Disease (CTAD2018)
22762
post-template-default,single,single-post,postid-22762,single-format-standard,ajax_fade,page_not_loaded,,select-theme-ver-4.4,wpb-js-composer js-comp-ver-5.4.7,vc_responsive

Neurotrope to Present Additional Phase 2 Data at the 11th Edition of Clinical Trials on Alzheimer’s Disease (CTAD2018)